Abstract: An online system trains a machine-learned lift prediction model configured as a neural network. The machine-learned lift prediction model can be used during the inference process to determine lift predictions for users and items associated with the online system. By configuring the lift prediction model as a neural network, the lift prediction model can capture and process information from users and items in various formats and more flexibly model users and items compared to existing methods. Moreover, the lift prediction model includes at least a first portion for generating control predictions and a second portion for generating treatment predictions, where the first portion and the second portion share a subset of parameters. The shared subset of parameters can capture information important for generating both control and treatment predictions even when the training data for a control group of users might be significantly smaller than that of the treatment group.

Abstract: An online system trains a machine-learned lift prediction model configured as a neural network. The machine-learned lift prediction model can be used during the inference process to determine lift predictions for users and items associated with the online system. By configuring the lift prediction model as a neural network, the lift prediction model can capture and process information from users and items in various formats and more flexibly model users and items compared to existing methods. Moreover, the lift prediction model includes at least a first portion for generating control predictions and a second portion for generating treatment predictions, where the first portion and the second portion share a subset of parameters. The shared subset of parameters can capture information important for generating both control and treatment predictions even when the training data for a control group of users might be significantly smaller than that of the treatment group.

Abstract: The present invention pertains to antibodies against a novel isoform of human PD1 protein (?42PD1) that contains a 42-nucleotide in-frame deletion in exon 2. The invention also pertains to methods of using the antibodies against ?42PD1 for the treatment for autoimmune disorders. In certain embodiments, the antibodies against ?42PD1 are monoclonal.

Abstract: The present invention pertains to antibodies against a novel isoform of human PD1 protein (?42PD1) that contains a 42-nucleotide in-frame deletion in exon 2. The invention also pertains to methods of using the antibodies against ?42PD1 for the treatment for autoimmune disorders. In certain embodiments, the antibodies against ?42PD1 are monoclonal.

Abstract: The present invention pertains to antibodies against a novel isoform of human PD1 protein (?42PD1) that contains a 42-nucleotide in-frame deletion in exon 2. The invention also pertains to methods of using the antibodies against ?42PD1 for the treatment for autoimmune disorders. In certain embodiments, the antibodies against ?42PD1 are monoclonal.

Abstract: The subject invention provides novel soluble PD-1 (sPD-1) proteins, nucleic acids, and fusion constructs thereof, for enhancing humoral and cell-mediated immunity of a subject. Also provided are therapeutic compositions comprising the sPD-1 proteins, nucleic acids, and fusion constructs of the subject invention. In a preferred embodiment, the therapeutic composition is formulated as a vaccine composition. Advantageously, the sPD-1 proteins, nucleic acids, and therapeutic compositions provide protective immunity against pathogenic infection including HIV infection. In addition, the subject invention can be used in the prevention and/or treatment of tumor or cancer.

Abstract: In one embodiment, the present invention provides a new isoform of human PD1 (?42PD1) that contains a 42-nucleotide in-frame deletion located at exon 2 domain. ?42PD1 does not engage PD-L1/PD-L2, and can induce the production of pro-inflammatory cytokines In one embodiment, ?42PD1 can be used as an intramolecular adjuvant to develop a fusion DNA vaccine for enhancing antigen-specific CD8+ T cell immunity and for prevention of pathogenic infection and/or cancer. In one embodiment, soluble ?42PD1 protein could be a therapeutic target for autoimmune diseases. In other embodiments, proteins or peptides or nucleic acids encoding proteins or peptides containing ?42PD1 could be used as immunogens for developing antibodies binding specifically to ?42PD1. In yet another embodiment, neutralizing antibodies could block s?42PD1 function and accordingly could be used as treatment for autoimmune disorders.

Abstract: The subject invention provides novel soluble PD-1 (sPD-1) proteins, nucleic acids, and fusion constructs thereof, for enhancing humoral and cell-mediated immunity of a subject. Also provided are therapeutic compositions comprising the sPD-1 proteins, nucleic acids, and fusion constructs of the subject invention. In a preferred embodiment, the therapeutic composition is formulated as a vaccine composition. Advantageously, the sPD-1 proteins, nucleic acids, and therapeutic compositions provide protective immunity against pathogenic infection including HIV infection. In additon, the subject invention can be used in the prevention and/or treatment of tumor or cancer.